The Motley Fool
05 Jul 2026, 15:16 UTC · 3h ago
IHE vs. PJP: Which Pharmaceutical ETF Is the Better Buy for Investors?
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
The Motley Fool
05 Jul 2026, 15:16 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
The iShares U.S. Pharmaceuticals ETF (IHE) has a high concentration risk, with Eli Lilly and Johnson & Johnson comprising approximately 44% of its portfolio. — Extreme concentration in two names makes the fund highly vulnerable to company-specific failures, such as failed clinical trials or regulatory setbacks.
-0.40IHE's heavy weighting in Eli Lilly has driven superior five-year returns and shallower drawdowns compared to PJP. — Demonstrates the positive alpha generated by high-conviction weighting in top-performing pharmaceutical leaders.
+0.30The Invesco Pharmaceuticals ETF (PJP) utilizes a more even position-weighting strategy across 29 companies to mitigate single-stock volatility. — Provides a lower-risk profile for investors, though it limits the potential for outsized gains from a single winner.
+0.10Continue reading
6 related stories
Top 3 movers · tap to explore
IHE offers a lower expense ratio (0.38% vs 0.57%) and a higher dividend yield (1.62% vs 0.96%) than PJP. — Lower costs and higher yield are marginally positive for long-term total returns and attractiveness to income investors.
+0.10Which stocks this story touches
Mentioned as one of the sector's strongest performers due to its weight-loss and diabetes drugs.
Identified as a proven blue chip name and a dominant holding in a successful ETF.
Mentioned only as a portfolio holding without qualitative analysis.
Mentioned only as a portfolio holding without qualitative analysis.
Mentioned only as a portfolio holding without qualitative analysis.
[mutual] Both are major US-based pharmaceutical companies and holdings in pharmaceutical ETFs.
[mutual] Both are major US-based pharmaceutical companies and core holdings in pharmaceutical ETFs.
[mutual] Both are major US-based pharmaceutical companies and holdings in pharmaceutical ETFs.
[mutual] Both are major US-based pharmaceutical companies and core holdings in pharmaceutical ETFs.
[mutual] Both are major US-based pharmaceutical companies and holdings in pharmaceutical ETFs.
[mutual] Both are major US-based pharmaceutical companies and holdings in pharmaceutical ETFs.
[mutual] Both are pharmaceutical companies listed as holdings in the PJP ETF.
[mutual] Both are pharmaceutical companies mentioned as holdings in pharmaceutical ETFs.
[mutual] Both are pharmaceutical companies listed as holdings in the PJP ETF.
[mutual] Both are pharmaceutical companies mentioned as holdings in pharmaceutical ETFs.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
24/7 Wall Street
31m ago
